Prevalence of Obesity in Patients with Psoriasis: Results of the National Study PsoHealth3

Dermatology

Volumn 231, Issue 3, 2015, Pages 231-238

  Jacobi, Arnd ^a   Langenbruch, Anna ^a   Purwins, Sandra ^a   Augustin, Matthias ^a   Radtke, Marc A ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Body mass index; Body weight; Obesity; Overweight; Psoriasis; Psoriasis Area and Severity Index

Indexed keywords

ADULT; AGED; ARTICLE; BODY MASS; CROSS-SECTIONAL STUDY; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; OUTPATIENT DEPARTMENT; PREVALENCE; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; CLINICAL TRIAL; COMPLICATION; GERMANY; MIDDLE AGED; MULTICENTER STUDY; PROCEDURES; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX;

BODY MASS INDEX; CROSS-SECTIONAL STUDIES; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; OBESITY; POPULATION SURVEILLANCE; PREVALENCE; PSORIASIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84942193236     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000433528     Document Type: Article

References (45)

1. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM; Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team: global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013;133:377-385.
2. Augustin M, Herberger K, Hintzen S, Heigel H, Franzke N, Schäfer I: Prevalence of skin lesions and need for treatment in a cohort of 90,880 workers. Br J Dermatol 2011;165:865-873.
3. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M: Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006;298:321-328.
4. Sterry W, Strober BE, Menter A; International Psoriasis Council: Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol 2007;157:649-655.
5. Augustin M, Reich K, Glaeske G, Schaefer I, Radtke M: Co-morbidity and age-related prevalence of psoriasis: analysis of health insurance data in Germany. Acta Derm Venereol 2010;90:147-151.
6. Reich K, Krüger K, Mössner R, Augustin M: Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1,511 patients with plaque-type psoriasis. Br J Dermatol 2009;160:1040-1047.
7. Augustin M, Reich K, Reich C, Purwins S, Rustenbach S, Schaefer I, Radtke M: Quality of psoriasis care in Germany - results of the national study PsoHealth 2007 . J Dtsch Dermatol Ges 2008;6:640-645.
8. Radtke MA, Reich K, Blome C, Rustenbach S, Augustin M: Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey. J Eur Acad Dermatol Venereol 2009;23:683-691.
9. Carrascosa JM, Rocamora V, Fernandez-Torres R: Obesity and psoriasis: inflammatory nature of obesity, relationship between psoriasis and obesity, and therapeutic implications. Actas Dermosifiliogr 2014;105:31-44.
10. Eckel RH, Grundy SM, Zimmet PZ: The metabolic syndrome. Lancet 2005;365:1415-1428.
11. Lyon CJ, Law RE, Hsueh WA: Minireview: adiposity, inflammation, and atherogenesis. Endocrinology 2003;144:2195-2200.
12. Mallbris L, Granath F, Masten A, Stahle M: Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol 2006;54:614-621.
13. Ni C, Chiu MW: Psoriasis and comorbidities: links and risks. Clin Cosmet Investig Dermatol 2014;7:119-132.
14. Wang Y, Chen J, Zhao Y, Geng L, Song F, Chen HD: Psoriasis is associated with increased levels of serum leptin. Br J Dermatol 2008;158:1134-1135.
15. Boehncke WH, Boehncke S, Tobin AM, Kirby B: The 'psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol 2011; 20: 303-307.
16. Gelfand JM, Mehta NN, Langan SM: Psoriasis and cardiovascular risk: strength in numbers, part II. J Invest Dermatol 2011;131:1007-1010.
17. Davidovici BB, Sattar N, Prinz J, Puig L, Emery P, Barker JN, van de Kerkhof P, Stahle M, Nestle FO, Girolomoni G, Krueger JG: Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol 2010;130:1785-1796.
18. Jacobi A, Kupke C, Behzad M, Hertl M: Comorbidities, metabolic risk profile and healthrelated quality of life in German patients with plaque-type psoriasis: a cross-sectional prospective study. Int J Dermatol 2013;52:1081-1087.
19. Fredriksson T, Pettersson U: Oral treatment of pustulosis palmo-plantaris with a new retinoid, Ro 10-9359. Dermatologica 1979;158:60-64.
20. Finlay AY, Khan GK: Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210-216.
21. Langenbruch A, Radtke M, Franzke N, Ring J, Foelster-Holst R, Augustin M: Quality of health care of atopic eczema in Germany: results of the national health care study Atopic-Health. J Eur Acad Dermatol Venereol 2014;28:719-726.
22. Statistisches Bundesamt: Gesundheitsberichterstattung des Bundes. Wiesbaden, Gesundheitsbericht für Deutschland, 2013.
23. Henseler T, Christophers E: Disease concomitance in psoriasis. J Am Acad Dermatol 1995;32:982-986.
24. McGowan JW, Pearce DJ, Chen J, Richmond D, Balkrishnan R, Feldman SR: The skinny on psoriasis and obesity. Arch Dermatol 2005;141:160-162.
25. Naldi L, Chatenoud L, Linder D, Belloni Fontana A, Peserico A, et al: Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005;125:61-67.
26. Herron MD, Hinckley M, Hoffman MS, Papenfuss J, Hansen CB, Callis KP, Krueger GG: Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005;141:1527-1534.
27. Engin B, Kutlubay Z, Yardimci G, Vehid HE, Ambarcioglu P, Serdaroglu S, Tüzün Y: Evaluation of body composition parameters in patients with psoriasis. Int J Dermatol 2014;53:1468-1473.
28. Hossain P, Kawar B, ElNahas M: Obesity and diabetes in the developing world - a growing challenge. N Engl J Med 2007;356:213-215.
29. Higa-Sansone G, Szomstein S, Soto F, Brasecso O, Cohen C, Rosenthal RJ: Psoriasis remission after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Obes Surg 2004;14:1132-1134.
30. Wolters M: Diet and psoriasis: experimental data and clinical evidence. Br J Dermatol 2005;153:706-714.
31. Jensen P, Zachariae C, Christensen R, Geiker NR, Schaadt BK, Stender S, Hansen PR, Astrup A, Skov L: Effect of weight loss on the severity of psoriasis: a randomized clinical study. JAMA Dermatol 2013;149:795-801.
32. Danielsen K, Wilsgaard T, Olsen AO, Eggen AE, Olsen K, Cassano PA, Furberg AS: Elevated odds of metabolic syndrome in psoriasis: a population-based study of age and gender differences. Br J Dermatol 2014;172:419-427.
33. Augustin M, Glaeske G, Radtke MA, Christophers E, Reich K, Schaefer I: Epidemiology and comorbidity of psoriasis in children. Br J Dermatol 2010;162:633-636.
34. Gelfand JM, Neimann AL, Shin DB, Wang X: Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296:1735-1741.
35. Wakee M, Thio HB, Prens EP, et al: Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Atherosclerosis 2007;190:1-9.
36. Mahiques-Santos L, Soriano-Navarro CJ, Perez-Pastor G, et al: Psoriasis and ischemic coronary artery disease. Actas Dermosifiliogr 2015;106:112-116.
37. Friedewald VE, Cather JC, Gelfand JM, et al: AJC editor's consensus: psoriasis and coronary artery disease. Am J Cardiol 2008;102:1631-1643.
38. Nast A, Boehncke WH, Mrowietz U, et al: German S3-guidelines on the treatment of psoriasis vulgaris (short version). Arch Dermatol Res 2012;304:87-113.
39. Gisondi P, Cotena C, Tessari G, Girolomoni G: Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol 2008;22:341-344.
40. Saraceno R, Schipani C, Mazzotta A, et al: Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis. Pharmacol Res 2008;57:290-295.
41. Florin V, Cottencin AC, Delaporte E, Staumont-Sallé D: Body weight increment in patients treated with infliximab for plaque psoriasis. J Eur Acad Dermatol Venereol 2013;27:186-190.
42. Gisondi P, Conti A, Galdo G, et al: Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study. Br J Dermatol 2013;168:1124-1127.
43. Puig L: Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. J Eur Acad Dermatol Venereol 2011;25:1007-1011.
44. Gisondi P, Del Giglio M, Di Francesco V, et al: Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. Am J Clin Nutr 2008;88:1242-1247.
45. Jin Y, Zhang F, Yang S, et al: Combined effects of HLA-Cw6, body mass index and waist-hip ratio on psoriasis vulgaris in Chinese Han population. J Dermatol Sci 2008;52:123-129.